
Partner
Carlton Fleming
- Capital Markets
- Emerging Companies and Venture Capital
CARLTON FLEMING represents high-growth private and public life sciences and technology companies in a wide range of matters, including formation and financing activities, corporate governance, public offerings, and SEC reporting and compliance. He also regularly advises corporate clients and their boards of directors and special committees on a wide variety of securities law and corporate governance matters. Since 2012, Carlton has been involved in over 60 IPOs and other public offerings, helping raise over $11 billion.
Experience
- Representative Matters
Carlton’s substantial experience includes the following representative matters:
- Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, in its initial public offering and multiple follow-on equity offerings.
- Cytokinetics, Incorporated, a biotech company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue, in its US$138 million offering of senior notes and multiple follow-on equity offerings.
- DocuSign, Inc., a provider of a leading eSignature solution, in its:
- US$723.7 million initial public offering;
- US$443.3 million follow-on equity offering and concurrent offering US$575 million 0.5% convertible senior notes due 2023; and
- US$188 million acquisition of Seal Software, a leading contract analytics and artificial intelligence technology provider.
- Kodiak Sciences Inc., a clinical stage company engaged in developing innovative therapeutics to treat high prevalence of ophthalmic diseases, in its:
- US$312 million and US$645 million follow-on equity offerings; and
- US$225 million royalty financing transaction.
- NGM Biopharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing transformative therapeutics for patients, on its US$106.7 million initial public offering and US$143.8 million follow-on offering.
- Talis Biomedical Corporation, a company developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, in its US$232.5 million initial public offering.
- Twilio Inc., a publicly traded cloud communications platform, in its US$1.8 billion public offering of Class A common stock and US$1.0 billion public offering of senior notes.
- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines, in its US$287.5 million initial public offering.
*Certain of the matters above were handled prior to joining Sidley
Capabilities
SERVICES AND INDUSTRIES
News & Insights
Credentials
Admissions & Certifications
- California
- North Carolina
Education
- Duke University School of Law, JD, LLM, 2007
- Duke University, B.A., 2004